Pervious studies indicated that the prevalence of bicuspid aortic valve（BAV） might be higher in China. There is a familial predisposition to the development of BAV. The study analyzed epidemiological data on selected BAV and established a BAV cohort to observe disease progression and treatment outcomes.
Eligibility
Sex
ALL
Min age
14 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:
* The patients were aged 14-60 years;
* Definitive diagnosis of BAV by imaging (echocardiography, aortic CTA, cardiac magnetic resonance, etc.)
* Patients were informed about the nature of the study and agreed to participate in all the terms of the study and signed an informed consent form approved by the ethics committee.
Exclusion Criteria:
* Poor patient compliance and inability to complete follow-up visits as required;
* Rheumatic heart valve disease, other organic valve disease.
* Hyperthyroidism, severe anemia, and other factors that significantly affect hemodynamics.
* Other circumstances that the researcher believes should be excluded.
Primary outcome measure(s)
SAVR / TAVR — 5 year Indications for surgical or transcatheter aortic valve replacement
Trial sites (1)
Facility
City
Region
Status
Ruijin hospital, Shanghai JiaoTong University School of Medicine
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.